Efficacy and tolerability of dietary supplement Catharsis Forte in patients with erectile dysfunction
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Abstract
Patients and methods. The sample population consisted of 30 patients with ED (EF IIEF = 17,6±0,16) and a mean age of 50±8 years. Effect of DS Catharsis Forte on erectile function was assessed using the EF IIEF total score and domains. Libido, orgasm, satisfac tion with sexual intercourse and sexual life in general to change the IIEF questionnaire respective domains. Treatment course: DS Catharsis Forte 1 capsule per os 1 time a day for 30 days.
Results. After 30 days of treatment DD Catharsis Forte in the group of patients with ED we registered a statistically significant and clinically meaningful improvement in the basic IIEF domains characteriz ing erection, libido, orgasm, satisfaction with sexual intercourse and sexuality in general. DS Catharsis Forte significantly (by an average of 10,4 points, p<0,05) increased the integral index of erectile function – total score EF IIEF, improves the ability of the patient to carry out introjection and maintain an erection sufficient for sexual intercourse, which was confirmed by an increase in the average values of the relevant questions of EF IIEF scale from 1,5 to 1,9 points. DS Catharsis Forte was well tolerated: adverse events occurred in patients receiving only one third of patients and limited transient tachycardia, facial flushing, nasal congestion (26,7%) and headache (3,3%) were mild and did not They demanded its abolition. No serious side effects were noted. The treatment course of DS Catharsis Forte for 30 days did not lead to pathological changes in the general analysis of blood and urine and blood chemistry.
Conclusion: The results of the study give reason to recommend DD Catharsis Forte for use in andrological practice in the treatment of men with impaired sexual function.
##plugins.themes.bootstrap3.article.details##
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.
References
Горпинченко И.И. Эректильная дисфункция: диагностика и современные методы лечения // Здоровье мужчины. – 2002. – No 1. – С. 9–11.
Горпинченко И.И., Мирошников Я.О. Эректильная дисфункция. – Л., «Медицина світу», 2003.
Сексология и андрология / Под ред. А.Ф. Возианова, И.И. Горпинченко. – К.: Абрис, 1997. – 880 с.
Capogrosso P., Colicchia M, Ventimiglia E, Castagna G, Clementi MC, Suardi N, Castiglione F, Briganti A, Cantiello F, Damiano R, Montorsi F, Salonia A. One patient out of four with newly diagnosed erectile dysfunction is a young man – worrisome picture from the everyday clinical practice. J Sex Med. – 2013 Jul;10(7):1833–41.
Hatzimouratidis K., Hatzichristou D. Phosphodiesterase type 5 inhibitors: unmet needs. //Curr. Pharm. Des. 2009; 15(30): 3476–85.
Jiann B.P., Yu C.C., Su C.C., Tsai J.Y. Compliance of sildenafil treatment for erectile dysfunction and factors affecting it. Int J Impot Res. 2006 Mar Apr;18(2):146–9.
Drewes SE, George J, Khan F. Recent findings on natural products with erectile dysfunction activity //Phytochemistry. 2003 Apr; 62(7): 1019–25.
Методичні рекомендації з клінічних випробувань лікарських засобів в Україні. – К.: МОРІОН, 1999. – C. 1–74.
Capelleri J.C., Rosen R.C., Smith M.D., Quirk F., Maytom M.C., Mishra A., Osterloh I.H. Some developments on the International Index of Erectile Dysfunction (IIEF) // Drug Information Journal, 1999. – Vol. 33. – Р. 179–190.
Rosen R.C., Riley A., Wagner G. et al. The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction // Urology. – 1997. – V. 49. – P. 822–830.
Гланц С. Медико-биологическая статистика. Пер. с англ. – М.: Практика, 1998. – 459 с.
